CG Oncology: Passing A Red Line For What I Would Call A Reasonable Valuation (Rating Downgrade) [Seeking Alpha]
CG Oncology, Inc. - Common stock (CGON)
Company Research
Source: Seeking Alpha
Cretostimogene grenadenorepvec remains the lead asset, targeting non-metastatic bladder cancer with pivotal data and a BLA submission expected in 2025-2026. A key upcoming catalyst is the PIVOT-006 topline readout, the first randomized registrational study in intermediate-risk non-muscle invasive bladder cancer. With a strengthened balance sheet and recent fundraising, CGON projects a cash runway extending into the first half of 2029. Octavian Lazar/iStock via Getty Images Topline Summary and Update When I last took a look at CG Oncology ( CGON ), I reaffirmed a cautious "Buy" sentiment even though the stock had been on the rise for some time. Since then, the stock
Show less
Read more
Impact Snapshot
Event Time:
CGON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CGON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CGON alerts
High impacting CG Oncology, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
CGON
News
- CG Oncology (CGON) had its price target raised by JPMorgan Chase & Co. from $65.00 to $91.00. They now have an "overweight" rating on the stock.MarketBeat
- CG Oncology (CGON) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=CGON&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sell" to "hoMarketBeat
- CG Oncology (CGON) had its price target raised by HC Wainwright from $80.00 to $100.00. They now have a "buy" rating on the stock.MarketBeat
- CG Oncology (CGON) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=CGON&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" to "MarketBeat
- This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know [Yahoo! Finance]Yahoo! Finance
CGON
Earnings
- 11/14/25 - In-Line
CGON
Sec Filings
- 4/17/26 - Form 144
- 4/16/26 - Form 4
- 4/16/26 - Form 4
- CGON's page on the SEC website